Reduced circulating oxidized LDL is associated with hypocholesterolemia and enhanced thiol status in Gilbert syndrome

Free Radical Biology and Medicine

Volumn 52, Issue 10, 2012, Pages 2120-2127

  Boon, Ai Ching ^a   Hawkins, Clare L ^b   Bisht, Kavita ^a   Coombes, Jeff S ^c   Bakrania, Bhavisha ^a   Wagner, Karl Heinz ^d   Bulmer, Andrew C ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b HEART RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bile pigment; Bilirubin; Cardiovascular disease; Free radicals; Glutathione; Thiol

Indexed keywords

ANTIOXIDANT; BILIRUBIN; GLUTATHIONE; LOW DENSITY LIPOPROTEIN; THIOL;

ADULT; ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GILBERT DISEASE; HUMAN; HYPOCHOLESTEROLEMIA; IN VIVO STUDY; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; BILIRUBIN; CHOLESTEROL; COHORT STUDIES; FEMALE; GILBERT DISEASE; GLUTATHIONE; HUMANS; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; RATS; SULFHYDRYL COMPOUNDS; YOUNG ADULT;

RATTUS NORVEGICUS;

EID: 84861047353     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.03.002     Document Type: Article

References (57)

1. Novotny, L.; Vitek, L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp. Biol. Med. (Maywood) 228:568-571; 2003.
2. Franchini, M.; Targher, G.; Lippi, G. Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons? Adv. Clin. Chem. 50:47-63; 2010.
3. Vitek, L.; Schwertner, H. A. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv. Clin. Chem. 43:1-57; 2007.
4. Hsieh, T. Y.; Shiu, T. Y.; Huang, S. M.; Lin, H. H.; Lee, T. C.; Chen, P. J.; Chu, H. C.; Chang, W. K.; Jeng, K. S.; Lai, M. M.; Chao, Y. C. Molecular pathogenesis of Gilberta's syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter. Pharmacogenet. Genomics 17:229-236; 2007.
5. Bulmer, A. C.; Blanchfield, J. T.; Toth, I.; Fassett, R. G.; Coornbes, J. S. Improved resistance to serum oxidation in Gilberta's syndrome: a mechanism for cardiovascular protection. Atherosclerosis 199:390-396; 2008.
6. Vitek, L.; Kraslova, I.; Muchova, L.; Novotny, L.; Yamaguchi, T. Urinary excretion of oxidative metabolites of bilirubin in subjects with Gilbert syndrome. J. Gastroenterol. Hepatol. 22:841-845; 2007.
7. Kalousova, M.; Novotny, L.; Zima, T.; Braun, M.; Vitek, L. Decreased levels of advanced glycation end-products in patients with Gilbert syndrome. Cell. Mol. Biol. (Noisy-le-grand) 51:387-392; 2005.
8. Stocker, R. Antioxidant activities of bile pigments. Antioxid. Redox Signaling 6:841-849; 2004.
9. Scott, J. R.; Chin, B. Y.; Bilban, M. H.; Otterbein, L. E. Restoring homeostasis: is heme oxygenase-1 ready for the clinic? Trends Pharmacol. Sci. 28:200-205; 2007.
10. Vitek, L.; Jirsa, M.; Brodanova, M.; Kalab, M.; Marecek, Z.; Danzig, V.; Novotny, L.; Kotal, P. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160:449-456; 2002.
11. McDonagh, A. F.; Lightner, D. A. 'Like a shrivelled blood orangea' - bilirubin, jaundice, and phototherapy. Pediatrics 75:443-455; 1985.
12. Ihara, H.; Hashizume, N.; Shimizu, N.; Aoki, T. Threshold concentration of unbound bilirubin to induce neurological deficits in a patient with type I Crigler-Najjar syndrome. Ann. Clin. Biochem. 36:347-352; 1999.
13. Dennery, P. A.; Mcdonagh, A. F.; Spitz, D. R.; Rodgers, P. A.; Stevenson, D. K. Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn-rats exposed tohyperoxia. Free Radic.Biol.Med. 19:395-404; 1995.
14. Kao, J. S.; Dawson, J. D.; Murray, J. C.; Dagle, J. M.; Berends, S. K.; Gillen, S. B.; Bell, E. F. Possible roles of bilirubin and breast milk in protection against retinopathy of prematurity. Acta Paediatr. 100:347-351; 2011.
15. Milner, J. D.; Aly, H. Z.; Ward, L. B.; El-Mohandes, A. Does elevated peak bilirubin protect from retinopathy of prematurity in very low birthweight infants. J. Perinatol. 23:208-211; 2003.
16. Hosono, S.; Ohno, T.; Kimoto, H.; Shimizu, M.; Nozawa, M.; Genkawa, R.; Yoshida, T.; Wada, S.; Harada, K. No clinical correlation between bilirubin levels and severity of retinopathy of prematurity. J. Pediatr. Ophthalmol. Strabismus 39:151-156; 2002.
17. Tell, G.; Gustincich, S. Redox state, oxidative stress, and molecular mechanisms of protective and toxic effects of bilirubin on cells. Curr. Pharm. Des. 15:2908-2914; 2009.
18. Stein, E. A.; Myers, G. L. National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin. Chem. 41:1421-1426; 1995.
19. National Cholesterol Education Program, U.S. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary. Bethesda: National Institutes of Health; 2001.
20. European Atherosclerosis Society Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur. Heart J. 8:77-88; 1987.
21. Miller, N. J.; Rice-Evans, C.; Davies, M. J.; Gopinathan, V.; Milner, A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clin. Sci. (London) 84:407-412; 1993.
22. Benzie, I. F.; Strain, J. J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal. Biochem. 239:70-76; 1996.
23. Friedewald, W. T.; Levy, R. I.; Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:499-502; 1972.
24. Wei, Y.; Ota, R. B.; Bowen, H. T.; Omaye, S. T. Determination of human plasma and leukocyte ascorbic acid by microtiter plate assay. J. Nutr. Biochem. 7:179-186; 1996.
25. Hawkins, C. L.; Morgan, P. E.; Davies, M. J. Quantification of protein modification by oxidants. Free Radic. Biol. Med. 46:965-988; 2009.
26. Levine, R. L.; Garland, D.; Oliver, C. N.; Amici, A.; Climent, I.; Lenz, A. G.; Ahn, B. W.; Shaltiel, S.; Stadtman, E. R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186:464-478; 1990.
27. Hissin, P. J.; Hilf, R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal. Biochem. 74:214-226; 1976.
28. Kumar, V.; Abbas, A.; Fausto, N.; Aster, J. Robbins and Cotran pathologic basis of disease. 8th edition. Philadelphia: Saunders/Elsevier; 2010.
29. Hagymási, K.; Kocsis, I.; Lengyel, G.; Sipos, P.; Fehér, J.; Blázovics, A. Further evidence of altered redox status of hyperbilirubinaemic patients: role of bilirubin in Gilbert syndrome. Acta Biol. Szeged. 47:131-134; 2003.
30. Giraudi, P. J.; Bellarosa, C.; Coda-Zabetta, C. D.; Peruzzo, P.; Tiribelli, C. Functional induction of the cystine-glutamate exchanger system XC-activity in SH-SY5Y cells by unconjugated bilirubin. PLoS ONE 6:e29078; 2011.
31. Pocobelli, G.; Peters, U.; Kristal, A. R.; White, E. Use of supplements of multivitamins, vitamin C, and vitamin E in relation to mortality. Am. J. Epidemiol. 170:472-483; 2009.
32. Muchova, L.; Vanova, K.; Zelenka, J.; Lenicek, M.; Petr, T.; Vejrazka, M.; Sticova, E.; Vreman, H. J.; Wong, R. J.; Vitek, L. Bile acids decrease intracellular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress. J. Cell. Mol. Med. 15:1156-1165; 2011.
33. Muchova, L.; Wong, R. J.; Hsu, M.; Morioka, I.; Vitek, L.; Zelenka, J.; Schroder, H.; Stevenson, D. K. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can. J. Physiol. Pharmacol. 85:800-810; 2007.
34. Neuzil, J.; Stocker, R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Lett. 331:281-284; 1993.
35. Minetti, M.; Mallozzi, C.; Di Stasi, A. M.; Pietraforte, D. Bilirubin is an effective antioxidant of peroxynitrite-mediated protein oxidation in human blood plasma. Arch. Biochem. Biophys. 352:165-174; 1998.
36. Radi, R.; Beckman, J. S.; Bush, K. M.; Freeman, B. A. Peroxynitrite oxidation of sulfhydryls: the cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 266:4244-4250; 1991.
37. Kaur, H.; Hughes, M. N.; Green, C. J.; Naughton, P.; Foresti, R.; Motterlini, R. Interaction of bilirubin and biliverdin with reactive nitrogen species. FEBS Lett. 543:113-119; 2003.
38. Mancuso, C.; Bonsignore, A.; Di Stasio, E.; Mordente, A.; Motterlini, R. Bilirubin and S-nitrosothiols interaction: evidence for a possible role of bilirubin as a scavenger of nitric oxide. Biochem. Pharmacol. 66:2355-2363; 2003.
39. Serdar, Z.; Aslan, K.; Dirican, M.; Sarandol, E.; Yesilbursa, D.; Serdar, A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. Clin. Biochem. 39:794-803; 2006.
40. Chevion, M.; Berenshtein, E.; Stadtman, E. R. Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic. Res. 33(Suppl.):S99-108; 2000.
41. Tapan, S.; Karadurmus, N.; Dogru, T.; Ercin, C. N.; Tasci, I.; Bilgi, C.; Kurt, I.; Erbil, M. K. Decreased small dense LDL levels in Gilbert†™s syndrome. Clin. Biochem. 44:300-303; 2011.
42. Yesilova, Z.; Serdar, M.; Ercin, C. N.; Gunay, A.; Kilciler, G.; Hasimi, A.; Uygun, A.; Kurt, I.; Erbil, M. K.; Dagalp, K. Decreased oxidation susceptibility of plasma low density lipoproteins in patients with Gilbert’s syndrome. J. Gastroenterol. Hepatol. 23:1556-1560; 2008.
43. Stocker, R.; Ames, B. N. Potential role of conjugated bilirubin and copper in the metabolism of lipid peroxides in bile. Proc. Natl. Acad. Sci. USA 84:8130-8134; 1987.
44. Ocadlik, I.; Hlinstakova, S.; Oravec, S. Relationship between unconjugated hyperbilirubinemia and lipoprotein spectrum. Neuro Endocrinol. Lett. 32:360-364; 2011.
45. Tapan, S.; Dogru, T.; Tasci, I.; Ercin, C. N.; Ozgurtas, T.; Erbil, M. K. Soluble CD40 ligand and soluble P-selectin levels in Gilberta's syndrome: a link to protection against atherosclerosis? Clin. Biochem. 42:791-795; 2009.
46. Lippi, G.; Targher, G.; Montagnana, M.; Salvagno, G. L.; Guidi, G. C. Bilirubin concentration and cardiovascular risk profile. Liver Int. 29:315-316; 2009.
47. Temme, E. H.; Zhang, J.; Schouten, E. G.; Kesteloot, H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 12:887-894; 2001.
48. Chin, H. J.; Cho, H. J.; Lee, T. W.; Na, K. Y.; Oh, K. H.; Joo, K. W.; Yoon, H. J.; Kim, Y. S.; Ahn, C.; Han, J. S.; Kim, S.; Jeon, E. S.; Jin, D. C.; Kim, Y. L.; Park, S. H.; Kim, C. D.; Song, Y. R.; Kim, S. G.; Kim, Y. G.; Lee, J. E.; Oh, Y. K.; Lim, C. S.; Lee, S. K.; Chae, D. W.; Cho, W. Y.; Kim, H. K.; Jo, S. K. The mildly elevated serum bilirubin level is negatively associated with the incidence of end stage renal disease in patients with IgA nephropathy. J. Korean Med. Sci. 24(Suppl.):S22-29; 2009.
49. Hwang, H. J.; Lee, S. W.; Kim, S. H. Relationship between bilirubin and C-reactive protein. Clin. Chem. Lab. Med. 49:1823-1828; 2011.
50. Horsfall, L. J.; Rait, G.; Walters, K.; Swallow, D. M.; Pereira, S. P.; Nazareth, I.; Petersen, I. Serum bilirubin and risk of respiratory disease and death. J. Am. Med. Assoc. 305:691-697; 2011.
51. Hwang, H. J.; Kim, S. H. Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin. Chim. Acta 411:1496-1501; 2010.
52. Dekker, D.; Dorresteijn, M. J.; Pijnenburg, M.; Heemskerk, S.; Rasing-Hoogveld, A.; Burger, D. M.; Wagener, F. A.; Smits, P. The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 31:458-463; 2011.
53. Nakayama, M.; Takahashi, K.; Komaru, T.; Fukuchi, M.; Shioiri, H.; Sato, K.; Kitamuro, T.; Shirato, K.; Yamaguchi, T.; Suematsu, M.; Shibahara, S. Increased expression of heme oxygenase-1 and bilirubin accumulation in foam cells of rabbit atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 21:1373-1377; 2001.
54. Stadler, N.; Lindner, R. A.; Davies, M. J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler. Thromb. Vasc. Biol. 24:949-954; 2004.
55. Stocker, R.; Keaney Jr. J. F. Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84:1381-1478; 2004.
56. McCarty, M. F. "Iatrogenic Gilbert syndromea" - a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med. Hypotheses 69:974-994; 2007.
57. Bulmer, A. C.; Coombes, J. S.; Blanchfield, J. T.; Toth, I.; Fassett, R. G.; Taylor, S. M. Bile pigment pharmacokinetics and absorption in the rat: therapeutic potential for enteral administration. Br. J. Pharmacol. 164:1857-1870; 2011.